FATE — Fate Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.82m
- $110.94m
- $6.65m
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Fate Therapeutics Appoints Laura Hamill To Board Of Directors
Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028
Brief: Fate Therapeutics Selected For U.S. FDA Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program To Support Manufacturing Readiness Of Ft819
Brief: Fate Therapeutics Announces Three Presentations At The 2026 Asgct Annual Meeting Highlighting Off-The-Shelf Car T-Cell Therapy Pipeline For Cancer And Autoimmune Diseases
Brief: Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Fate Therapeutics reports lower Q4 collaboration revenue
Brief: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Fate Therapeutics Q3 net loss widens
Brief: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule
Brief: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Fate Therapeutics Reports New Employee Inducement Awards
Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Fate Therapeutics Reports First Quarter 2025 Financial Results And Business Updates